Hoffmann-La Roche, AstraZeneca and Pfizer side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Hoffmann-La Roche | AstraZeneca | Pfizer |
|---|---|---|---|
| Phase 1 | Hoffmann-La Roche: 33 of its 80 programs at phase 1
and 28 more — sign in to see them all | AstraZeneca: 25 of its 118 programs at phase 1
and 20 more — sign in to see them all | Pfizer: 42 of its 91 programs at phase 1
and 37 more — sign in to see them all |
| Phase 2 | Hoffmann-La Roche: 18 of its 80 programs at phase 2
and 13 more — sign in to see them all | AstraZeneca: 47 of its 118 programs at phase 2
and 42 more — sign in to see them all | Pfizer: 10 of its 91 programs at phase 2
and 5 more — sign in to see them all |
| Phase 3 | Hoffmann-La Roche: 22 of its 80 programs at phase 3
and 17 more — sign in to see them all | AstraZeneca: 28 of its 118 programs at phase 3
and 23 more — sign in to see them all | Pfizer: 31 of its 91 programs at phase 3
and 26 more — sign in to see them all |
| Approved, new studies | Hoffmann-La Roche: 7 of its 80 programs at approved, new studies
and 2 more — sign in to see them all | AstraZeneca: 18 of its 118 programs at approved, new studies
and 13 more — sign in to see them all | Pfizer: 8 of its 91 programs at approved, new studies
and 3 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoffmann-La Roche28 readouts · 7 phase 3 | Hoffmann-La Roche, Nov ’26: 4 programs whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion
| Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Feb ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion
| Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3
| Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion
| Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Hoffmann-La Roche, Jul ’27: 3 programs whose next study reaches primary completion
| Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion
| Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · |
| AstraZeneca61 readouts · 15 phase 3 | AstraZeneca, Nov ’26: 7 programs whose next study reaches primary completion
and 2 more — sign in to see them all | AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3
and 2 more — sign in to see them all | AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3
and 7 more — sign in to see them all | AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3
and 2 more — sign in to see them all | AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion
| AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3
| AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion
| AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion
| AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion
| AstraZeneca, Oct ’27: 4 programs whose next study reaches primary completion
|
| Pfizer37 readouts · 10 phase 3 | Pfizer, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3
| Pfizer, Dec ’26: 8 programs whose next study reaches primary completion, 2 in phase 3
and 3 more — sign in to see them all | Pfizer, Jan ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Feb ’27: 5 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Mar ’27: 3 programs whose next study reaches primary completion
| Pfizer, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, May ’27: 2 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Jun ’27: 3 programs whose next study reaches primary completion
| · | Pfizer, Aug ’27: 4 programs whose next study reaches primary completion, 1 in phase 3
| Pfizer, Sep ’27: 3 programs whose next study reaches primary completion, 2 in phase 3
| Pfizer, Oct ’27: 3 programs whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 19, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Hoffmann-La Roche
New programs 6
- RO7836748phase 1 · first study · Oct 23
- RO7821657phase 1 · first study · Oct 14
- RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
- RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive
- RO7568282phase 2 · first study · Aug 20 · Parkinson Disease
- RO7890597phase 1 · first study · Aug 19
Reached a new phase 1
- petrelintidephase 3 · Sep 11 · Obesity
Study stopped 1
- RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813
Primary completion later 10
- emicizumabphase 3 · Apr 2027 → Oct 2027 (+5 mo) · moved Nov 16 · NCT06998524
- mosunetuzumabphase 2 · Feb 2028 → Aug 2028 (+5 mo) · moved Nov 16 · NCT07598396
- inavolisibphase 3 · Dec 2026 → May 2027 (+4 mo) · moved Nov 13 · NCT05894239
- glofitamabphase 2 · Jan 2027 → Jul 2029 (+30 mo) · moved Nov 10 · NCT06806033
- sefaxersenphase 3 · Aug 2026 → May 2028 (+21 mo) · moved Oct 5 · NCT05797610
- giredestrantphase 3 · Dec 2027 → Jun 2028 (+5 mo) · moved Oct 2 · NCT05296798
+4 more
- hyaluronidase (human recombinant)phase 3 · Dec 2027 → Jun 2028 (+5 mo) · moved Oct 2 · NCT05296798
- tifeglipronphase 2 · Nov 2026 → Feb 2028 (+14 mo) · moved Oct 1 · NCT07112872
- giredestrantphase 3 · Oct 2027 → Dec 2027 (+2 mo) · moved Sep 29 · NCT05296798
- hyaluronidase (human recombinant)phase 3 · Oct 2027 → Dec 2027 (+2 mo) · moved Sep 29 · NCT05296798
AstraZeneca
New programs 2
- CT204V-CD19 × CD20phase 2 · first study · Nov 6
- AZD0543phase 1 · first study · Aug 28 · Paramyxoviridae Infections
Reached a new phase 1
- BFF MDIphase 3 · Nov 6 · Asthma
Study stopped 0
None
Primary completion later 23
- AZD4954phase 1 · Dec 2026 → Mar 2027 (+3 mo) · moved Nov 13 · NCT07812077
- laroprovstatphase 3 · Jul 2025 → Feb 2027 (+20 mo) · moved Nov 13 · NCT06834932
- saruparibphase 1 · Oct 2026 → Dec 2026 (+3 mo) · moved Nov 12 · NCT06713369
- elecoglipronphase 1 · Oct 2026 → Jan 2027 (+4 mo) · moved Nov 10 · NCT07534592
- rilvegostomigphase 2 · Aug 2026 → Jun 2028 (+21 mo) · moved Nov 10 · NCT04995523
- rosuvastatinphase 1 · Oct 2026 → Jan 2027 (+4 mo) · moved Nov 10 · NCT07534592
+17 more
- ALXN2230phase 1 · Dec 2026 → Aug 2027 (+8 mo) · moved Nov 5 · NCT07352423
- monalizumabphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Nov 4 · NCT05221840
- oleclumabphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Nov 4 · NCT05221840
- Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512phase 2 · Mar 2028 → Jul 2028 (+4 mo) · moved Nov 2 · NCT07123454
- vemzatatug vedotinphase 2 · Aug 2027 → Jan 2028 (+5 mo) · moved Oct 30 · NCT06106945
- surovatamigphase 2 · Jun 2029 → May 2030 (+11 mo) · moved Oct 28 · NCT06564038
- trastuzumab deruxtecanphase 3 · Nov 2026 → May 2027 (+6 mo) · moved Oct 22 · NCT04784715
- Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Oct 2028 → Nov 2028 (+1 mo) · moved Oct 21 · NCT07735637
- surovatamigphase 2 · Apr 2028 → Oct 2028 (+6 mo) · moved Oct 20 · NCT07571746
- Anti-CD22/Topoisomerase I Inhibitor Antibody-drug Conjugate AZD4512phase 2 · Apr 2028 → Oct 2028 (+5 mo) · moved Oct 15 · NCT07109219
- datopotamab deruxtecanphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Oct 15 · NCT06417814
- osimertinibphase 3 · Sep 2026 → Jan 2027 (+3 mo) · moved Oct 15 · NCT06417814
- acalabrutinibphase 3 · Jan 2027 → Apr 2027 (+3 mo) · moved Oct 5 · NCT03836261
- elecoglipronphase 3 · Jun 2027 → Apr 2028 (+10 mo) · moved Oct 1 · NCT07775404
- AZD9550phase 2 · Aug 2026 → Oct 2026 (+3 mo) · moved Sep 29 · NCT07017179
- lenbelintidephase 2 · Aug 2026 → Oct 2026 (+3 mo) · moved Sep 29 · NCT07017179
- Anti-Claudin18.2/Anti-CD3 Bispecific Antibody AZD5863phase 2 · Jul 2027 → Mar 2029 (+20 mo) · moved Sep 25 · NCT06005493
Pfizer
New programs 6
- PF-08166744phase 1 · first study · Nov 5
- PF-08161842phase 1 · first study · Oct 20 · Alzheimer Disease
- PF-08165784phase 1 · first study · Oct 20 · Breast Neoplasms
- PF-08098488phase 1 · first study · Oct 12 · Esophageal Neoplasms
- PF-08656795phase 1 · first study · Oct 9 · Obesity
- PG4 Multivalent Vaccinephase 3 · first study · Aug 26 · Pneumococcal Infections
Reached a new phase 0
None
Study stopped 3
- PF-07868489phase 2 · terminated Nov 2 · none of its studies left running“The study terminated due to a business decision and was not based on any safety and/or efficacy concerns.” · NCT07073820
- vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 20 participants enrolled in Ph 1b. T…” · NCT05573555
- vepdegestrantphase 2 · terminated Oct 27“Enrollment was permanently closed for strategic business reasons after 11 participants enrolled in Ph1b. Th…” · NCT06125522
Primary completion later 6
- mevrometostatphase 3 · Dec 2026 → Feb 2027 (+2 mo) · moved Oct 30 · NCT06551324
- mevrometostatphase 3 · Dec 2026 → Sep 2027 (+10 mo) · moved Oct 30 · NCT06629779
- PF-07328948phase 2 · Nov 2027 → May 2028 (+6 mo) · moved Oct 23 · NCT06991257
- rimegepantphase 3 · Aug 2028 → Feb 2030 (+18 mo) · moved Oct 23 · NCT06616194
- atirmociclibphase 2 · Sep 2026 → Oct 2029 (+36 mo) · moved Oct 21 · NCT04557449
- tivunatamigphase 3 · Jul 2031 → Jan 2032 (+6 mo) · moved Sep 28 · NCT07392892
Where they overlap
Conditions where at least two of them have programs: 64 in all, the first 12 here. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25, AstraZeneca: 5, Pfizer: 9).